Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205679 | 0.95 | MAPK8 (0.44) | MAPK8MAPK14 | |
| SCHEMBL5206712 | 0.89 | MAPK8 (0.42) | MAPK8MAPK14 | |
| SCHEMBL5206869 | 0.88 | MAPK14 (0.42) | MAPK14 | |
| SCHEMBL5204251 | 0.87 | MAPK14 (0.41) | MAPK8MAPK14 | |
| SCHEMBL5209554 | 0.85 | MAPK14 (0.42) | MAPK14 | |
| SCHEMBL5207204 | 0.85 | MAPK14 (0.40) | MAPK14 | |
| SCHEMBL5209640 | 0.85 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL5272213 | 0.85 | MAPK14 (0.45) | MAPK14 | |
| SCHEMBL5209335 | 0.84 | MAPK14 (0.47) | MAPK14 | |
| SCHEMBL5207590 | 0.84 | MAPK14 (0.44) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802590-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | Pharmacia & Upjohn Company LLC (US) | 2007-07-04 | — | — | EP | claimed |
| WO-2006040666-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-04-20 | — | — | WO | claimed |
| US-10441577-B2 | Medicament for treatment of liver cancer | HELMHOLTZ ZENTRUM FUER INFEKTIONSFORSCHUNG (DE) | 2019-10-15 | — | — | US | disclosed |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| EP-1802590-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | Pharmacia & Upjohn Company LLC (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040666-A1 | SUBSTITUTED N-ALKYLPYRIMIDINONES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441577-B2 | Medicament for treatment of liver cancer | PYGL, PFKL, GLS2 | MAPK8 740/4885MAPK14 523/4885 |
| US-20150079154-A1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | PYGL, PFKL, GLS2 | MAPK8 740/4885MAPK14 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.